Folate-targeted nanostructured chitosan/chondroitin sulfate complex carriers for enhanced delivery of bortezomib to colorectal cancer cells.
Bortezomib
Chitosan chondroitin sulfate
Colorectal cancer
Folic acid
Journal
Asian journal of pharmaceutical sciences
ISSN: 2221-285X
Titre abrégé: Asian J Pharm Sci
Pays: Netherlands
ID NLM: 101535338
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
14
08
2018
revised:
10
09
2018
accepted:
23
09
2018
entrez:
28
2
2020
pubmed:
28
2
2020
medline:
28
2
2020
Statut:
ppublish
Résumé
Folate-targeting self-assembled nanoparticles (NPs) using biocompatible and biodegradable natural polymers chitosan (Cs) and chondroitin sulfate (Chs) were developed to address the major challenge in cancer treatment, the selective delivery of nanoparticles to the target site. In this study, we successfully incorporated a hydrophobic drug, bortezomib (Bor), into folic acid (FA)-conjugated Cs/Chs self-assembled NPs (Bor/Cs/Chs-FA) for colorectal cancer therapy. The particle size and polydispersity index of Bor/Cs/Chs-FA were ∼196.5 ± 1.2 nm and ∼0.21 ± 0.5, respectively. A pH-dependent release profile was observed, facilitating cancer cell-targeted drug release under an acidic tumor microenvironment. Moreover,
Identifiants
pubmed: 32104437
doi: 10.1016/j.ajps.2018.09.004
pii: S1818-0876(18)30842-0
pmc: PMC7032194
doi:
Types de publication
Journal Article
Langues
eng
Pagination
40-51Informations de copyright
© 2018 Shenyang Pharmaceutical University. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.
Références
Materials (Basel). 2015 Aug 28;8(9):5647-5670
pubmed: 28793528
Colloids Surf B Biointerfaces. 2017 Jul 1;155:83-92
pubmed: 28410515
Carbohydr Res. 2011 May 1;346(6):801-6
pubmed: 21397214
Carbohydr Polym. 2017 Jan 20;156:276-284
pubmed: 27842824
Int J Nanomedicine. 2012;7:4391-408
pubmed: 22927757
J Control Release. 2001 Jun 15;73(2-3):255-67
pubmed: 11516503
J Colloid Interface Sci. 2018 Nov 1;529:34-43
pubmed: 29883928
Sci Rep. 2017 Apr 10;7:43299
pubmed: 28393891
Cell Signal. 2013 Jan;25(1):308-18
pubmed: 23079083
Sci Rep. 2016 Jul 29;6:30782
pubmed: 27469490
Mater Sci Eng C Mater Biol Appl. 2017 Dec 1;81:542-550
pubmed: 28888008
Colloids Surf B Biointerfaces. 2008 Aug 1;65(1):69-73
pubmed: 18440788
Int J Biol Macromol. 2014 Mar;64:353-67
pubmed: 24360899
J Nanosci Nanotechnol. 2015 Jul;15(7):4753-73
pubmed: 26373036
J Pharm Investig. 2018;48(1):43-60
pubmed: 30546919
Nanomedicine (Lond). 2017 Jun;12(12):1511-1523
pubmed: 28573923
Mater Sci Eng C Mater Biol Appl. 2015 Nov 1;56:294-304
pubmed: 26249593
AAPS PharmSciTech. 2010 Mar;11(1):36-45
pubmed: 20017011
Artif Cells Nanomed Biotechnol. 2016 Dec;44(8):1979-1987
pubmed: 26754823
Int J Pharm. 2017 Mar 15;519(1-2):11-21
pubmed: 28069389
Cancers (Basel). 2011 Jul 15;3(3):2888-903
pubmed: 24212938
Eur J Pharm Biopharm. 2015 Nov;97(Pt B):417-26
pubmed: 26614560
J Am Chem Soc. 2013 Jan 16;135(2):933-40
pubmed: 23253016
Biomed Res Int. 2015;2015:172458
pubmed: 26579531
PLoS One. 2013;8(2):e55705
pubmed: 23383345
Nanomedicine. 2017 Apr;13(3):885-896
pubmed: 27993720
Arch Pharm Res. 2018 Feb;41(2):111-129
pubmed: 29214601
Int J Pharm. 2017 Aug 7;528(1-2):692-704
pubmed: 28642202
Carbohydr Polym. 2017 Oct 1;173:57-66
pubmed: 28732901
Toxicol Res. 2015 Mar;31(1):61-8
pubmed: 25874034
Chem Sci. 2017 Jan 1;8(1):63-77
pubmed: 28451149
Oncol Rep. 2015 Sep;34(3):1087-96
pubmed: 26151224
Int J Biol Macromol. 2014 Aug;69:532-41
pubmed: 24950310
ACS Appl Mater Interfaces. 2014 May 14;6(9):6709-16
pubmed: 24697646
Pak J Pharm Sci. 2014 Jan;27(1):129-37
pubmed: 24374435
Small. 2012 May 21;8(10):1596-606
pubmed: 22411637
Drug Deliv. 2017 Nov;24(1):1262-1272
pubmed: 28891336
Colloids Surf B Biointerfaces. 2018 Oct 1;170:718-728
pubmed: 30005409
Int J Pharm. 2016 Oct 15;512(1):75-86
pubmed: 27558884
Drug Deliv. 2017 Nov;24(1):1690-1702
pubmed: 29098877